Combination of monoclonal immunoglobulin deposition disease (MIDD) and immunotactoid glomerulopathy (ITG) is a rare form of monoclonal immunoglobulin (MIg)-associated renal disease. We retrospectively reviewed the native kidney biopsy specimens at Peking University People’s Hospital from 2011 to 2020. Five patients were diagnosed as MIDD + ITG. Their clinical and pathological characteristics were studied. The typical clinical features were nephritic syndrome and renal dysfunction with prominent anemia, but hematuria was mild. Unlike single MIDD and single ITG, on light microscopy, segmentally distributed mesangial nodular sclerosis on the basis of mesangial matrix hyperplasia was the major lesion. Others including membranoproliferative glomerulonephritis (MPGN)-like lesion, glomerular basement membrane thickness, and mild to moderate mesangial and endothelial proliferations might presented at the same time and in the same glomeruli. On immunofluorescence, MIg, usually monoclonal light chains, deposited along glomerular basement membranes and tubular basement membranes, while the intact MIg or monoclonal heavy chain deposited in the mesangial regions. Corresponding to the depositions on immunofluorescence, punctate “powdery” deposits along glomerular basement membranes and tubular basement membranes under electronic microscopy indicated the presence of MIDD. Microtubular substructures (diameters of 20–50 nm) exhibiting hollow cores arranged in parallel arrays in mesangial regions indicated the presence of ITG. Patients treated with bortezomib-based regimen seemed to have better outcomes. In conclusion, MIDD + ITG is a rare combination form of MIg-associated renal disease. Accurate diagnosis requires the comprehensive pathological investigations.
Background: Type I cryoglobulinemia consists of a single monoclonal immunoglobulin and can induce small-vessel vasculitis with renal involvement. Cryoglobulinemic glomerulonephritis is a rare manifestation, pathologically characterized by membranoproliferative glomerulonephritis (MPGN). In this report, we present a case of type I cryoglobulinemic renal injury characterized by crystalline cryoglobulinemic glomerulonephritis type I. Our objective is to provide a detailed insight into the presentation, underlying diseases, diagnosis, treatment, and outcomes of crystalline cryoglobulinemic glomerulonephritis type I. Case presentation: A 38-year-old man presented with acute kidney injury (AKI) without any other systemic symptoms. A kidney biopsy confirmed the presence of abundant pseudothrombi within the glomerular capillary lumens, with no significant proliferative lesions observed. Immunofluorescence microscopy (IF) demonstrated strong, diffuse, homogeneous staining for IgG 1 and Lambda light chain. Electron microscopy revealed a microtubular substructure characteristic of nephropathy. Following the initial course of rituximab, plasma exchange (PE), and methylprednisolone, the treatment yielded successful results. However, renal dysfunction recurred 18 months later, prompting a second renal biopsy, which exhibited findings similar to the first. Additionally, bone marrow biopsy identified an aberrant monotypic plasma cell clone. Subsequently, daratumumab therapy was initiated, leading to a recovery in kidney function. Conclusion: In nephropathies associated with crystalline cryoglobulinemic glomerulonephritis type I, renal and bone marrow biopsies play a crucial role in establishing the diagnosis and determining the optimal therapeutic approach. It is essential to consider primary diseases prior to selecting the initial management strategy.